RecallRadar

FDA Drug recall D-0237-2026

Cisatracurium Besylate Injection USP, 200mg/20mL*(10mg/mL), 10 x 20 mL Single-dose Vials per Carton, Rx Only, Manufactured for: Somerset Th…

On 2025-12-24 the FDA classified a Class III recall of Cisatracurium Besylate Injection USP, 200mg/20mL*(10mg/mL), 10 x 20 mL Single-dose Vials per Carton, Rx Only, Manufactured for: Somerset Th… by Somerset Therapeutics, citing subpotent product:out of specification assay results observed during long term stability testing.

Read the official FDA Drug notice

AgencyFDA Drug
Recall numberD-0237-2026
ClassificationClass III
Statusongoing
Initiated2025-11-26
Published2025-12-24
Last updated2026-09-13 11:52 UTC
CompanySomerset Therapeutics
DistributionUS

Product

Cisatracurium Besylate Injection USP, 200mg/20mL*(10mg/mL), 10 x 20 mL Single-dose Vials per Carton, Rx Only, Manufactured for: Somerset Therapeutics, LLC, Hollywood, FL 33024, Made in India, Single dose 20mL vial NDC 70069-151-01; 10 x 20 Single dose vials per Carton, NDC 70069-151-10.

Reason

Subpotent product:out of specification assay results observed during long term stability testing.

Identifiers

ndc70069-141-01
ndc70069-141-10
ndc70069-151-01
ndc70069-151-10
code_infoLot #: A250020, Exp Date 06/30/2026

Status history

No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:52 UTC. Current status: ongoing.

Source

Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0237-2026%22

RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.